Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Investor Relations

EDAP Stock - EDAP TMS S A Stock Trading


home / stock / edap

EDAP EDAP Quote EDAP Short EDAP News EDAP Articles EDAP Message Board

MWN AI Summary *

EDAP TMS S.A. (NASDAQ: EDAP) is a medical technology company headquartered in Lyon, France, specializing in the development, manufacturing, and commercialization of innovative treatments for urological disorders. Founded in 1979, EDAP has positioned itself as a leader in the fields of kidney stone management and prostate cancer treatment, leveraging advanced therapeutic technologies to enhance patient care.

One of the company's flagship products is the High-Intensity Focused Ultrasound (HIFU) device, known as the Focal One. This cutting-edge technology is designed for the minimally invasive treatment of localized prostate cancer, providing an alternative to traditional surgical methods while preserving surrounding healthy tissue. The Focal One device has gained traction in various markets, benefiting from the increasing demand for less invasive treatment options.

EDAP also offers a range of products focused on the management of kidney stones, including its patented UroPulse laser platform. This system effectively fragments kidney stones, enabling quicker and more efficient treatment in urological procedures.

In recent years, EDAP has pursued strategic growth opportunities, including expanding its commercial footprint in the U.S. and securing partnerships for additional regulatory approvals. The company has showcased its commitment to innovation by investing in research and development to enhance its product offerings and explore new therapeutic areas.

Financially, EDAP has demonstrated resilience and growth potential, with a focus on increasing revenue through expanded sales and heightened market awareness of its offerings. As the healthcare landscape evolves toward more patient-centric and minimally invasive treatment options, EDAP TMS S.A. stands out as a promising player within the medical device sector, bolstered by a solid product pipeline and a strategic focus on key markets.

MWN AI Analysis *

EDAP TMS S.A. (NASDAQ: EDAP) is a company specialized in the development and commercialization of minimally invasive medical devices for urology. As of October 2023, EDAP holds a promising position within the healthcare sector, driven by its robust lineup of treatments for urological conditions, particularly its high-intensity focused ultrasound (HIFU) technology.

**Market Analysis:**

EDAP has shown consistent revenue growth, particularly through the adoption of its HIFU technology for the treatment of prostate cancer. With increasing awareness of innovative treatment options and a growing preference for minimally invasive procedures, EDAP is well-positioned to capitalize on a rising market demand. The company's strategic focus on expanding its international footprint also enhances its growth prospects. Partnerships with healthcare providers across Europe and the U.S. have bolstered its market presence.

**Financial Performance:**

EDAP's recent quarterly reports indicate a steady increase in sales, signaling strong demand. Analysts should monitor operational efficiency ratios and profit margins to assess the sustainability of this growth. Investing in R&D continues to be a key focus, ensuring that their product offerings remain competitive.

**Investment Considerations:**

While EDAP presents a sound investment opportunity, potential investors must remain vigilant regarding market volatility and regulatory challenges. The healthcare sector often experiences shifts in reimbursement policies and competition from larger firms, which could impact EDAP's market share.

**Conclusion:**

As a long-term investment, EDAP TMS S.A. appears to offer considerable potential driven by growth in minimally invasive surgery, a strong product pipeline, and increasing market trends favoring patient-centric care. Nonetheless, investors should perform thorough due diligence, with an eye on broader market conditions and company performance metrics to make informed decisions. A diversified approach is advised to mitigate risks associated with individual stocks in the healthcare sector.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | EDAP TMS S.A. (NASDAQ:EDAP)

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its global activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

Quote | EDAP TMS S.A. (NASDAQ:EDAP)

Last:$1.54
Change Percent: -1.69%
Open:$1.5599
Close:$1.54
High:$1.5688
Low:$1.52
Volume:32,315
Last Trade Date Time:07/09/2025 03:15:57 pm

News | EDAP TMS S.A. (NASDAQ:EDAP)

  • EDAP Announces Transition from Foreign Private Issuer to U.S. Domestic Filer Status

    Transition to U.S. reporting status to take effect on January 1, 2026 AUSTIN, Texas, July 1, 2025 - EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, announced a change in its U.S. reporting status. EDAP TM...

    • July 01, 2025 07:00:00 am

    • |
    • GlobeNewswire
    • |
      • EDAP Stock
      • EDAP Quote
      • EDAP Short
      • EDAP News
      • EDAP Articles
      • EDAP Message Board
  • EDAP TMS S.A. (EDAP) Q1 2025 Earnings Call Transcript

    2025-05-15 10:08:31 ET EDAP TMS S.A. (HAGHY) Q1 2025 Earnings Conference Call May 15, 2025, 08:30 AM ET Company Participants John Fraunces - IR, LifeSci Advisors Ryan Rhodes - CEO Ken Mobeck - CFO Conference Call Participants Michael Sarcone - Jefferi...

    • May 15, 2025 10:08:31 am

    • |
    • SeekingAlpha
    • |
      • EDAP Stock
      • EDAP Quote
      • EDAP Short
      • EDAP News
      • EDAP Articles
      • EDAP Message Board

Message Board Posts | EDAP TMS S.A. (NASDAQ:EDAP)

Subject By Source When
whytestocks: $EDAP News Article - EDAP Announces Regulatory Clearance of ExactVu Micro-Ultrasound in whytestocks investorshangout 04/06/2023 5:25:47 PM
whytestocks: $EDAP News Article - EDAP Announces Record Q4 US Focal One Placements whytestocks investorshangout 01/05/2023 4:20:47 PM
Anyone interested now?? Good report pop to $20 djohn investorshub 11/16/2022 10:40:54 PM
whytestocks: $EDAP News Article - EDAP TMS SA to Announce Third Quarter 2022 Financial Results on We whytestocks investorshangout 11/02/2022 3:30:57 PM
whytestocks: $EDAP News Article - EDAP's Focal One HIFU to be Showcased at Two Major Robotics & Urol whytestocks investorshangout 06/28/2022 3:50:51 PM

MWN AI FAQ **

What recent advancements or innovations has EDAP TMS S.A. EDAP made in the field of urology, and how do they compare to industry competitors?

EDAP TMS S.A. has recently advanced its minimally invasive urology treatments with innovations like the Focal One® device for real-time MRI-guided focused ultrasound, positioning it competitively against traditional therapies and enhancing precision and patient outcomes.

How has the financial performance of EDAP TMS S.A. EDAP evolved over the past few quarters, particularly in terms of revenue and net income?

EDAP TMS S.A. has shown a positive trend in financial performance over the past few quarters, with revenue growth driven by increased demand for its medical devices and treatments, while net income has also improved, reflecting improved operational efficiency and cost management.

What strategic partnerships or collaborations is EDAP TMS S.A. EDAP pursuing to enhance its market presence?

EDAP TMS S.A. is pursuing strategic partnerships with healthcare institutions and technology companies to enhance its market presence, focusing on expanding its reach in minimally invasive medical solutions and fostering innovation in urology and oncology treatments.

How does EDAP TMS S.A. EDAP plan to adapt its business model in response to evolving regulations in the healthcare sector?

EDAP TMS S.A. plans to adapt its business model by focusing on innovative product development, enhancing regulatory compliance protocols, and collaborating with key stakeholders to ensure alignment with evolving healthcare regulations and market demands.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.

Stock Information

Get EDAP Alerts

News, Short Squeeze, Breakout and More Instantly...

EDAP TMS S.A. Company Name:

EDAP Stock Symbol:

NASDAQ Market:

-1.69% G/L:

$1.54 Last:

32,315 Volume:

$1.5599 Open:

$1.54 Close:

EDAP TMS S.A. Website:

EDAP TMS S.A. Logo

Ad

Investor Relations
RECENT EDAP NEWS
  • EDAP - EDAP Announces Transition from Foreign Private Issuer to U.S. Domestic Filer Status

    Transition to U.S. reporting status to take effect on January 1, 2026 AUSTIN, Texas, July 1, 2025 - EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, announced a change in its U.S. reporting status. EDAP TM...

  • EDAP - Expected US Company Earnings on Thursday, May 15th, 2025

    Replimune Group Inc. (REPL) is expected to report $-0.75 for Q4 2025 Adcore (ADCOF) is expected to report for Q1 2025 Equillium Inc. (EQ) is expected to report $-0.22 for Q1 2025 Credicorp Ltd. (BAP) is expected to report $5.31 for Q1 2025 Pelangio Exploration Inc (PGXPF) is expec...

  • EDAP - EDAP Reports First Quarter 2025 Financial Results

    Achieved a Record Number of Focal One ® Robotic HIFU System Placements for a First Quarter Period Received CE Mark Designation for Focal One for the Treatment of Deep Infiltrating Endometriosis Positive Final Results of FARP Randomized Controlled Trial Presented at American Urolo...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get EDAP Alerts

Get EDAP Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1